Jardiance (Empagliflozin) is a diabetes drug developed by Boehringer Ingelheim Pharmaceuticals. Li Zhang, a chemist at Boehringer Ingelheim, discusses the journey of developing Empagliflozin from initial discovery through clinical trials to market approval as Jardiance. The development process involved optimizing the drug's properties through chemical modifications from an initial dose of 1 gram down to an approved daily dose.